Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.71 - $2.62 $4,617 - $7,074
-2,700 Reduced 48.21%
2,900 $5,000
Q2 2024

Aug 14, 2024

BUY
$1.97 - $3.62 $9,456 - $17,376
4,800 Added 600.0%
5,600 $11,000
Q1 2024

May 15, 2024

SELL
$1.18 - $2.71 $6,608 - $15,176
-5,600 Reduced 87.5%
800 $2,000
Q4 2023

Feb 14, 2024

SELL
$1.01 - $1.62 $3,535 - $5,670
-3,500 Reduced 35.35%
6,400 $8,000
Q3 2023

Nov 14, 2023

BUY
$1.39 - $1.72 $12,788 - $15,824
9,200 Added 1314.29%
9,900 $15,000
Q2 2023

Aug 14, 2023

SELL
$1.7 - $2.6 $170 - $260
-100 Reduced 12.5%
700 $1,000
Q1 2023

May 15, 2023

SELL
$1.81 - $4.0 $362 - $800
-200 Reduced 20.0%
800 $1,000
Q4 2022

Feb 14, 2023

BUY
$3.27 - $5.5 $3,270 - $5,500
1,000 New
1,000 $3,000

Others Institutions Holding INCR

About Intercure Ltd.


  • Ticker INCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,133,900
  • Market Cap $64.5M
  • Description
  • InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 a...
More about INCR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.